Acquired Resistance to Decitabine and Cross-resistance to Gemcitabine During the Long-term Treatment of Human HCT116 Colorectal Cancer Cells with Decitabine

Overview

Journal Oncol Lett

Specialty Oncology

Date 2015 Dec 2

PMID 26622566

Citations 7

Authors

Mika Hosokawa

Mai Saito

Aiko Nakano

Sakura Iwashita

Ayano Ishizaka

Kumiko Ueda

Seigo Iwakawa

Affiliations

Soon will be listed here.

Abstract

The aim of the present study was to determine the effects of long-term exposure of decitabine (DAC) to HCT116 colorectal cancer (CRC) cells on the acquisition of resistance to DAC as well as cross-resistance to anticancer drugs used for CRC or other epigenetic modifiers. In the present study, DAC-resistant HCT116 CRC cells were established through long-term treatment with increasing concentrations of DAC (10 to 540 nM); and the cross-resistance to other drugs was subsequently examined. DAC-resistant HCT116 cells were obtained following a 104-day treatment with DAC, including DAC-free intervals. The results demonstrated that the IC value of DAC was increased ~100-fold in DAC-resistant HCT116 cells. Messenger (m)RNA expression of , which is regulated by DNA methylation, was not detected in DAC-resistant cells; however, mRNA was present in HCT116 cells treated with DAC for 52 days. DNA methyltransferase 1 (DNMT1) protein levels were slightly decreased until day 81 and then returned to control levels in DAC-resistant cells. Further experiments using DAC-resistant HCT116 cells revealed that these cells exhibited cross-resistance to gemcitabine (Gem); however, cross-resistance was not observed for other DNMT inhibitors (azacitidine and zebularine), histone deacetylase inhibitors (trichostatin A, vorinostat and valproic acid) or anticancer drugs for CRC (5-fluorouracil, irinotecan and oxaliplatin). Furthermore, the protein expression levels of cytidine deaminase (CDA) were increased, while those of deoxycytidine kinase (dCK) were decreased in DAC-resistant HCT116 cells; by contrast, the mRNA expression levels for these proteins were not significantly altered. In conclusion, the results of the present study indicated that the long-term treatment of HCT116 cells with DAC led to the acquisition of resistance to both DAC and Gem. In addition, these results may be partly attributed to changes in CDA and/or dCK, which are involved in metabolic pathways common to these two drugs.

Citing Articles

Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy.

Taib N, Merhi M, Inchakalody V, Mestiri S, Hydrose S, Makni-Maalej K J Transl Med. 2023; 21(1):235.

PMID: 37004094 PMC: 10067322. DOI: 10.1186/s12967-023-04073-y.

Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines.

Kutyna M, Loone S, Saunders V, White D, Kok C, Hiwase D Int J Mol Sci. 2023; 24(4).

PMID: 36834962 PMC: 9965596. DOI: 10.3390/ijms24043553.

Gemcitabine resistance in triple-negative breast cancer cells can be reverted by deoxyribonucleoside kinase in the nucleus or cytosol.

Zhao Y, Jiang H, Gu M, Zu C, Zheng X Oncol Lett. 2020; 20(5):247.

PMID: 32973960 PMC: 7509507. DOI: 10.3892/ol.2020.12109.

Modulation of the Endothelin System in Colorectal Cancer Liver Metastasis: Influence of Epigenetic Mechanisms?.

Mahdi M, Georges R, Ali D, Bedeer R, Eltahry H, Gabr A Front Pharmacol. 2020; 11:180.

PMID: 32194414 PMC: 7063057. DOI: 10.3389/fphar.2020.00180.

HDAC2 Inhibitor Valproic Acid Increases Radiation Sensitivity of Drug-Resistant Melanoma Cells.

Kalal B, Pai V, Behera S, Somashekarappa H Med Sci (Basel). 2019; 7(3).

PMID: 30909413 PMC: 6473314. DOI: 10.3390/medsci7030051.

References

Christman J . 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002; 21(35):5483-95. DOI: 10.1038/sj.onc.1205699. View

Kakumoto M, Takara K, Sakaeda T, Tanigawara Y, Kita T, Okumura K . MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs. Biol Pharm Bull. 2002; 25(12):1604-7. DOI: 10.1248/bpb.25.1604. View

Damia G, Broggini M . Cell cycle checkpoint proteins and cellular response to treatment by anticancer agents. Cell Cycle. 2003; 3(1):46-50. View

Lyons J, Bayar E, Fine G, McCullar M, Rolens R, Rubinfeld J . Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies. Curr Opin Investig Drugs. 2004; 4(12):1442-50. View

Suzuki H, Watkins D, Jair K, Schuebel K, Markowitz S, Chen W . Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet. 2004; 36(4):417-22. DOI: 10.1038/ng1330. View

Issa J . CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004; 4(12):988-93. DOI: 10.1038/nrc1507. View

Wong M, Medrano J . Real-time PCR for mRNA quantitation. Biotechniques. 2005; 39(1):75-85. DOI: 10.2144/05391RV01. View

Marquez V, Kelley J, Agbaria R, Ben-Kasus T, Cheng J, Yoo C . Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. Ann N Y Acad Sci. 2006; 1058:246-54. DOI: 10.1196/annals.1359.037. View

Baylin S, Ohm J . Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer. 2006; 6(2):107-16. DOI: 10.1038/nrc1799. View

10.

Mini E, Nobili S, Caciagli B, Landini I, Mazzei T . Cellular pharmacology of gemcitabine. Ann Oncol. 2006; 17 Suppl 5:v7-12. DOI: 10.1093/annonc/mdj941. View

11.

Stordal B, Pavlakis N, Davey R . Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. Cancer Treat Rev. 2007; 33(4):347-57. DOI: 10.1016/j.ctrv.2007.01.009. View

12.

Cashen A, Shah A, Todt L, Fisher N, DiPersio J . Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol. 2007; 61(5):759-66. DOI: 10.1007/s00280-007-0531-7. View

13.

Ueno H, Kiyosawa K, Kaniwa N . Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?. Br J Cancer. 2007; 97(2):145-51. PMC: 2360307. DOI: 10.1038/sj.bjc.6603860. View

14.

Fedier A, Dedes K, Imesch P, von Bueren A, Fink D . The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Int J Oncol. 2007; 31(3):633-41. View

15.

Kihslinger J, Godley L . The use of hypomethylating agents in the treatment of hematologic malignancies. Leuk Lymphoma. 2007; 48(9):1676-95. DOI: 10.1080/10428190701493910. View

16.

de Jonge H, Fehrmann R, de Bont E, Hofstra R, Gerbens F, Kamps W . Evidence based selection of housekeeping genes. PLoS One. 2007; 2(9):e898. PMC: 1976390. DOI: 10.1371/journal.pone.0000898. View

17.

Qin T, Jelinek J, Si J, Shu J, Issa J . Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. Blood. 2008; 113(3):659-67. PMC: 2628372. DOI: 10.1182/blood-2008-02-140038. View

18.

Dedes K, Dedes I, Imesch P, von Bueren A, Fink D, Fedier A . Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities. Anticancer Drugs. 2009; 20(5):321-33. DOI: 10.1097/CAD.0b013e3283262a32. View

19.

Imesch P, Dedes K, Furlato M, Fink D, Fedier A . MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells. Int J Oncol. 2009; 35(3):631-40. DOI: 10.3892/ijo_00000375. View

20.

Qiu X, Hother C, Ralfkiaer U, Sogaard A, Lu Q, Workman C . Equitoxic doses of 5-azacytidine and 5-aza-2'deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome. PLoS One. 2010; 5(9). PMC: 2947512. DOI: 10.1371/journal.pone.0012994. View